Mitchell G. Lawrence

4.7k total citations · 1 hit paper
54 papers, 2.4k citations indexed

About

Mitchell G. Lawrence is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Mitchell G. Lawrence has authored 54 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 22 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Mitchell G. Lawrence's work include Prostate Cancer Treatment and Research (31 papers), Cancer Cells and Metastasis (8 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers). Mitchell G. Lawrence is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), Cancer Cells and Metastasis (8 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers). Mitchell G. Lawrence collaborates with scholars based in Australia, United States and Canada. Mitchell G. Lawrence's co-authors include Gail P. Risbridger, Judith A. Clements, Clare Stirzaker, Susan J. Clark, Ruth Pidsley, Elena Zotenko, Beverly S. Mühlhäusler, Susan Van Djik, Peter L. Molloy and Timothy J. Peters and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Mitchell G. Lawrence

53 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling

2016 832 citations Ruth Pidsley, Mitchell G. Lawrence et al. profile →

Peers

Countries citing papers authored by Mitchell G. Lawrence

Since Specialization

Citations

This map shows the geographic impact of Mitchell G. Lawrence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell G. Lawrence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell G. Lawrence more than expected).

Fields of papers citing papers by Mitchell G. Lawrence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell G. Lawrence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell G. Lawrence. The network helps show where Mitchell G. Lawrence may publish in the future.

Co-authorship network of co-authors of Mitchell G. Lawrence

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell G. Lawrence. A scholar is included among the top collaborators of Mitchell G. Lawrence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell G. Lawrence. Mitchell G. Lawrence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study). 2025 ·Journal of Clinical Oncology ·Megan Crumbaker, (unknown), Mitchell G. Lawrence, Leonard D. Goldstein, Andrew O. Yam, (unknown), Stephen Begbie, Robert Zielinski, W. Fox, (unknown), (unknown), (unknown), Emmanuel S. Antonarakis, Samuel R. Denmeade, Anthony M. Joshua	0
2	Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor 2024 ·BMC Cancer ·Daisuke Obinata, Ken‐ichi Takayama, Mitchell G. Lawrence, (unknown), Makoto Hara, Birunthi Niranjan, (unknown), Renea A. Taylor, Gail P. Risbridger, Satoru Takahashi, Satoshi Inoue	4
3	FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer 2024 ·Nature Communications ·Zifeng Wang, Scott L. Townley, (unknown), (unknown), Mu‐Qing Li, (unknown), Susan Patalano, (unknown), Kellee R. Siegfried, Jill A. Macoska, Dong Han, Shuai Gao, Gail P. Risbridger, Renea A. Taylor, Mitchell G. Lawrence, Housheng Hansen He, Luke A. Selth, Changmeng Cai	13
4	Abstract PR004: Second generation RNA Polymerase I inhibitor PMR-116 targets ribsomal RNA synthesis to potently treat a broad spectrum of malignancies 2024 ·Molecular Cancer Therapeutics ·Rita Ferreira, Katherine M. Hannan, Kostya I. Panov, (unknown), Amee J. George, (unknown), (unknown), Eric Kusnadi, (unknown), Mitchell G. Lawrence, Mustapha Haddach, Denis Drygin, Luc Furic, Ross D. Hannan, Nadine Hein	1
5	Advances in preclinical models of prostate cancer for research discovery 2023 ·Journal of Endocrinology ·Renea A. Taylor, Mitchell G. Lawrence, (unknown)	1
6	CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition 2021 ·Molecular Cancer Therapeutics ·Mitchell G. Lawrence, Laura H. Porter, (unknown), David Pook, Jeremy Grummet, Carmel Pezaro, Shahneen Sandhu, Susanne Ramm, (unknown), Andrew Bakshi, David L. Goode, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Kaylene J. Simpson, Renea A. Taylor, Gail P. Risbridger, Luc Furic	17
7	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids 2021 ·SLAS DISCOVERY ·(unknown), Susanne Ramm, (unknown), Jean M. Winter, Luke A. Selth, Amy R. Dwyer, Mark Frydenberg, Jeremy Grummet, Shahneen Sandhu, Theresa E. Hickey, Wayne D. Tilley, Renea A. Taylor, Gail P. Risbridger, Mitchell G. Lawrence, Kaylene J. Simpson	46
8	Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels 2020 ·Clinical Epigenetics ·(unknown), Phuc‐Loi Luu, Jenny Z. Song, Wenjia Qu, Gail P. Risbridger, Mitchell G. Lawrence, Jennifer Lu, Matt Trau, Darren Korbie, Susan J. Clark, Ruth Pidsley, Clare Stirzaker	17
9	Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer 2020 ·Clinical Epigenetics ·Mitchell G. Lawrence, Ruth Pidsley, Birunthi Niranjan, Melissa Papargiris, Brooke Pereira, Michelle G. Richards, (unknown), Sam Norden, Anthony J. Ryan, Mark Frydenberg, Clare Stirzaker, Renea A. Taylor, Gail P. Risbridger, Susan J. Clark	22
10	Cancer Plasticity: The Role of mRNA Translation 2020 ·Trends in cancer ·Laura Lee, David Papadopoli, Michael Jewer, Sonia V. del Rincón, Ivan Topisirović, Mitchell G. Lawrence, Lynne‐Marie Postovit	50
11	PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer 2019 ·Laura H. Porter, Mitchell G. Lawrence, (unknown), Shahneen Sandhu, Hong Wang, David Pook, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Luc Furic, Renea A. Taylor, Gail P. Risbridger	2
12	Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment 2019 ·Molecular & Cellular Proteomics ·Elizabeth V. Nguyen, Brooke Pereira, Mitchell G. Lawrence, Xiuquan Ma, Richard J. Rebello, Howard Chan, Birunthi Niranjan, (unknown), Stuart J. Ellem, Xiaoqing Guan, Jianmin Wu, Joanna N. Skhinas, Thomas R. Cox, Gail P. Risbridger, Renea A. Taylor, Natalie L. Lister, Roger J. Daly	77
13	Tissue engineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating cancer-associated fibroblast (CAF)-induced morphometric transition in vitro 2019 ·Biomaterials ·Brooke Pereira, Natalie L. Lister, Kohei Hashimoto, (unknown), María Flandes‐Iparraguirre, (unknown), (unknown), Birunthi Niranjan, Mark Frydenberg, Melissa Papargiris, Mitchell G. Lawrence, Renea A. Taylor, Dietmar W. Hutmacher, Stuart J. Ellem, Gail P. Risbridger, Elena M. De‐Juan‐Pardo	43
14	A preclinical xenograft model of prostate cancer using human tumors 2013 ·Nature Protocols ·Mitchell G. Lawrence, Renea A. Taylor, Roxanne Toivanen, John Pedersen, Sam Norden, David Pook, Mark Frydenberg, (unknown), Melissa Papargiris, Birunthi Niranjan, Michelle G. Richards, Hong Wang, Anne T. Collins, Norman J. Maitland, Gail P. Risbridger	75
15	Kallikrein 14 is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness 2012 ·Faculty of Health; Institute of Health and Biomedical Innovation ·Felicity Lose, Mitchell G. Lawrence, Srilakshmi Srinivasan, Tracy A. O’Mara, Louise Marquart, Suzanne K. Chambers, Robert A. Gardiner, Joanne F. Aitken, Amanda B. Spurdle, Jyotsna Batra, Judith A. Clements	1
16	Primary Culture and Propagation of Human Prostate Epithelial Cells 2012 ·Methods in molecular biology ·Birunthi Niranjan, Mitchell G. Lawrence, Melissa Papargiris, Michelle G. Richards, (unknown), Mark Frydenberg, John Pedersen, Renea A. Taylor, Gail P. Risbridger	13
17	Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells 2011 ·The Prostate ·Mitchell G. Lawrence, Naira V. Margaryan, Daniela Loessner, (unknown), (unknown), (unknown), Elisabeth A. Seftor, Carson Stephens, John Lai, (unknown), Lynne‐Marie Postovit, Judith A. Clements, Mary J.C. Hendrix	87
18	Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression 2007 ·Journal of Cellular Physiology ·Honor J. Hugo, (unknown), Tony Blick, Mitchell G. Lawrence, Judith A. Clements, Elizabeth D. Williams, Erik W. Thompson	45
19	The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition 2006 ·Biological Chemistry ·Astrid K. Whitbread, Tara Veveris‐Lowe, Mitchell G. Lawrence, David Nicol, Judith A. Clements	1
20	Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells 2005 ·Endocrine Related Cancer ·Tara Veveris‐Lowe, Mitchell G. Lawrence, (unknown), Laura Bui, Adrian C. Herington, Dianne Nicol, Judith A. Clements	128

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact